Literature DB >> 23714045

The antipsychotic-like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodents.

Anna Sławińska1, Joanna M Wierońska, Katarzyna Stachowicz, Marcin Marciniak, Magdalena Lasoń-Tyburkiewicz, Piotr Gruca, Mariusz Papp, Magdalena Kusek, Krzysztof Tokarski, Darío Doller, Andrzej Pilc.   

Abstract

BACKGROUND AND
PURPOSE: Because agonists at metabotropic glutamate receptors exert beneficial effects in schizophrenia, we have assessed the actions of Lu AF21934 and Lu AF32615, two chemically distinct, selective and brain-penetrant positive allosteric modulators (PAMs) of the mGlu4 receptor, in several tests reflecting positive, negative and cognitive symptoms of schizophrenia in rodents. EXPERIMENTAL APPROACH: Hyperactivity induced by MK-801 or amphetamine and head twitches induced by 2,5-dimethoxy-4-iodoamphetamine (DOI) in mice were used as models for positive symptoms. Disruption of social interaction and spatial delayed alternation tests induced by MK-801 in rats were used as models for negative and cognitive symptoms of schizophrenia, respectively. KEY
RESULTS: Lu AF21934 (0.1-5 mg·kg(-1) ) and Lu AF32615 (2-10 mg·kg(-1) ) dose-dependently inhibited hyperactivity induced by MK-801 or amphetamine. They also antagonized head twitches and increased frequency of spontaneous excitatory postsynaptic currents (EPSCs) in brain slices, induced by DOI. In mice lacking the mGlu4 receptor (mGlu4 (-/-) ) mice, Lu AF21934 did not antagonize DOI-induced head twitches. MK-801-induced disruption in the social interaction test was decreased by Lu AF21934 at 0.5 mg·kg(-1) and by Lu AF32615 at 10 mg·kg(-1) . In the delayed spatial alternation test, Lu AF21934 was active at 1 and 2 mg·kg(-1) , while Lu AF32615 was active at 10 mg·kg(-1) . CONCLUSIONS AND IMPLICATIONS: We propose that activation by PAMs of the mGlu4 receptor is a promising approach to the discovery of novel antipsychotic drugs.
© 2013 The British Pharmacological Society.

Entities:  

Keywords:  Lu AF21934; Lu AF32615; mGlu receptors; positive allosteric modulation; schizophrenia

Mesh:

Substances:

Year:  2013        PMID: 23714045      PMCID: PMC3753838          DOI: 10.1111/bph.12254

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  63 in total

1.  Guide to Receptors and Channels (GRAC), 5th edition.

Authors:  Stephen P H Alexander; Alistair Mathie; John A Peters
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

Review 2.  Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia.

Authors:  D C Javitt
Journal:  Hillside J Clin Psychiatry       Date:  1987

3.  Effects of atypical antipsychotic agents on social behavior in rodents.

Authors:  R Corbett; H Hartman; L L Kerman; A T Woods; J T Strupczewski; G C Helsley; P C Conway; R W Dunn
Journal:  Pharmacol Biochem Behav       Date:  1993-05       Impact factor: 3.533

4.  Comparative electrophysiology of pyramidal and sparsely spiny stellate neurons of the neocortex.

Authors:  D A McCormick; B W Connors; J W Lighthall; D A Prince
Journal:  J Neurophysiol       Date:  1985-10       Impact factor: 2.714

5.  Antiparkinsonian action of a selective group III mGlu receptor agonist is associated with reversal of subthalamonigral overactivity.

Authors:  S Lopez; L Jouve; N Turle-Lorenzo; L Kerkerian-Legoff; P Salin; M Amalric
Journal:  Neurobiol Dis       Date:  2012-01-08       Impact factor: 5.996

6.  The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice.

Authors:  J M Wierońska; M Kusek; K Tokarski; J Wabno; W Froestl; A Pilc
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

7.  DOI-induced deficits in prepulse inhibition in Wistar rats are reversed by mGlu2/3 receptor stimulation.

Authors:  Lena Wischhof; Helena E A Aho; Michael Koch
Journal:  Pharmacol Biochem Behav       Date:  2012-03-25       Impact factor: 3.533

8.  Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.

Authors:  G J Marek; R A Wright; D D Schoepp; J A Monn; G K Aghajanian
Journal:  J Pharmacol Exp Ther       Date:  2000-01       Impact factor: 4.030

Review 9.  Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.

Authors:  Susan Duty
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

Review 10.  Schizophrenia.

Authors:  Kim T Mueser; Susan R McGurk
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

View more
  22 in total

Review 1.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

Review 2.  Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders.

Authors:  Daniel J Foster; P Jeffrey Conn
Journal:  Neuron       Date:  2017-05-03       Impact factor: 17.173

3.  The Trace Kynurenine, Cinnabarinic Acid, Displays Potent Antipsychotic-Like Activity in Mice and Its Levels Are Reduced in the Prefrontal Cortex of Individuals Affected by Schizophrenia.

Authors:  Martina Ulivieri; Joanna Monika Wierońska; Luana Lionetto; Katiuscia Martinello; Paulina Cieslik; Agnieszka Chocyk; Martina Curto; Luisa Di Menna; Luisa Iacovelli; Anna Traficante; Francesca Liberatore; Giada Mascio; Nico Antenucci; Giuseppe Giannino; Matteo Vergassola; Anna Pittaluga; Valeria Bruno; Giuseppe Battaglia; Sergio Fucile; Maurizio Simmaco; Ferdinando Nicoletti; Andrzej Pilc; Francesco Fazio
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

4.  NMDA receptor-mediated synaptic transmission in prefrontal neurons underlies social memory retrieval in female mice.

Authors:  Yu-Xiang Zhang; Bo Xing; Yan-Chun Li; Chun-Xia Yan; Wen-Jun Gao
Journal:  Neuropharmacology       Date:  2021-11-20       Impact factor: 5.250

Review 5.  Advantages and Limitations of Animal Schizophrenia Models.

Authors:  Magdalena Białoń; Agnieszka Wąsik
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

Review 6.  Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia.

Authors:  Shalini Dogra; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2022-03-03       Impact factor: 4.054

7.  Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders.

Authors:  Mikhail Kalinichev; Emmanuel Le Poul; Christelle Boléa; Françoise Girard; Brice Campo; Massimiliano Fonsi; Isabelle Royer-Urios; Susan E Browne; Jason M Uslaner; Matthew J Davis; Jacob Raber; Robert Duvoisin; Simon T Bate; Ian J Reynolds; Sonia Poli; Sylvain Celanire
Journal:  J Pharmacol Exp Ther       Date:  2014-06-19       Impact factor: 4.030

8.  Input-specific regulation of glutamatergic synaptic transmission in the medial prefrontal cortex by mGlu2/mGlu4 receptor heterodimers.

Authors:  Zixiu Xiang; Xiaohui Lv; Xin Lin; Daniel E O'Brien; Molly K Altman; Craig W Lindsley; Jonathan A Javitch; Colleen M Niswender; P Jeffrey Conn
Journal:  Sci Signal       Date:  2021-04-06       Impact factor: 8.192

Review 9.  The Role of G Protein-Coupled Receptors (GPCRs) and Calcium Signaling in Schizophrenia. Focus on GPCRs Activated by Neurotransmitters and Chemokines.

Authors:  Tomasz Boczek; Joanna Mackiewicz; Marta Sobolczyk; Julia Wawrzyniak; Malwina Lisek; Bozena Ferenc; Feng Guo; Ludmila Zylinska
Journal:  Cells       Date:  2021-05-17       Impact factor: 6.600

10.  The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT₁A signalling.

Authors:  Joanna M Wierońska; Francine C Acher; Anna Sławińska; Piotr Gruca; Magdalena Lasoń-Tyburkiewicz; Mariusz Papp; Andrzej Pilc
Journal:  Psychopharmacology (Berl)       Date:  2013-03-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.